Heart Failure
‘Dealing with a time bomb’: Persistent tobacco smoking tied to cardiac injury at young age
In a cohort of English youths, those who persisted smoking tobacco from childhood to early adulthood showed significant cardiac damage by age 24 years and potentially irreversible cardiac injury, a researcher reported.
Misdiagnosis of heart failure possible in patients with COPD
PHILADELPHIA — Heart failure with preserved ejection fraction may be misdiagnosed in patients with COPD due to symptoms/signs being misinterpreted as COPD, according to a presentation at the 2024 GOLD COPD International Conference.
‘Very small amounts’ of intense physical activity may cut heart disease risk for women
Among nonexercising women, those who initiated a few minutes of vigorous lifestyle physical activity daily had substantially lower risk for any major adverse cardiovascular event, including myocardial infarction and heart failure, data show.
Patients with rheumatoid arthritis at higher risk for ‘avoidable’ hospitalization
WASHINGTON — Patients with rheumatoid arthritis demonstrate an elevated risk for avoidable hospitalizations, particularly for cardiovascular complications, compared with healthy controls, according to data presented at ACR Convergence 2024.
Breast calcification on mammogram ‘especially predictive’ of CVD risk in younger women
Breast arterial calcification seen on routine mammograms, especially among younger women, is associated with increased risk for death and adverse cardiovascular outcomes, including heart failure, myocardial infarction and stroke, data show.
Potassium binder helps optimize spironolactone use in patients with HF, hyperkalemia risk
CHICAGO — A potassium binder helped patients with HF who have or are at high risk for hyperkalemia stay on spironolactone at an optimal dose, but showed a signal of HF hospitalization risk, researchers reported.
Heart failure drug may be ‘cardioprotective strategy’ for high-risk patients with cancer
CHICAGO — Treatment with the heart failure medication sacubitril/valsartan was associated with a lower risk for chemotherapy-related heart damage among high-risk patients with cancer, according to preliminary results of the SARAH trial.
Nasal spray form of bumetanide may be just as good as oral, IV
CHICAGO — A novel nasal spray formulation of bumetanide, a commonly used diuretic for patients with HF, had similar safety, tolerability, relative bioavailability and pharmacodynamics to the oral and IV versions, researchers reported.
In PCI for MI, spironolactone does not meet primary endpoints but may show benefit in HF
CHICAGO — In patients with acute MI who underwent PCI, spironolactone did not improve the primary composite outcomes but was linked to reduced risk for new or worsening HF, according to new data from the CLEAR SYNERGY (OASIS-9) trial.
IV GLP-1 does not reduce death, stroke, organ damage after heart surgery
CHICAGO — Exenatide, an IV GLP-1 receptor agonist, did not improve clinical outcomes compared with placebo in patients undergoing heart surgery, according to the results of the GLORIOUS trial.